• 1. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 2. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 3. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 4. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 5. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoquinolines and derivatives Isoquinolines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoquinolines and derivatives

Isoquinoline, 1-methyl-, 2-oxide: Chemical Profile and Recent Research Applications

Isoquinoline, 1-methyl-, 2-oxide (CAS No. 3222-65-9) is a heterocyclic organic compound that has garnered significant attention in the field of medicinal chemistry and pharmacology due to its unique structural properties and biological activities. This compound, characterized by a fused benzene and pyridine ring system with a methyl group at the 1-position and an oxide group at the 2-position, exhibits a range of pharmacological effects that make it a valuable scaffold for drug discovery.

The chemical structure of Isoquinoline, 1-methyl-, 2-oxide contributes to its diverse biological interactions. The presence of the N-oxide functionality enhances its solubility in polar solvents and influences its metabolic pathways, making it a versatile intermediate in synthetic chemistry. Additionally, the methyl group at the 1-position introduces steric and electronic effects that can modulate the compound's binding affinity to biological targets.

Recent research has highlighted the potential of Isoquinoline, 1-methyl-, 2-oxide as a lead compound in the development of novel therapeutic agents. Studies have demonstrated its efficacy in various preclinical models, particularly in the context of central nervous system (CNS) disorders. The compound has shown promise as an antagonist for certain neurotransmitter receptors, which could lead to new treatments for neurological conditions such as epilepsy and chronic pain.

In addition to its CNS applications, Isoquinoline, 1-methyl-, 2-oxide has been investigated for its anti-inflammatory and antioxidant properties. Research indicates that this compound can modulate inflammatory pathways by interacting with key enzymes and transcription factors involved in the immune response. Its ability to scavenge reactive oxygen species also suggests potential benefits in combating oxidative stress-related diseases.

The synthesis of Isoquinoline, 1-methyl-, 2-oxide has been optimized through various methodologies, including oxidative cyclization of appropriate precursors. Advances in synthetic techniques have enabled the production of this compound in higher yields and purities, facilitating its use in more complex drug development programs. The growing interest in heterocyclic compounds like Isoquinoline, 1-methyl-, 2-oxide underscores their importance as building blocks for innovative pharmaceuticals.

One of the most compelling aspects of Isoquinoline, 1-methyl-, 2-oxide is its structural diversity, which allows for modifications at multiple positions to tailor its biological activity. Researchers have explored derivatives of this compound with enhanced pharmacokinetic profiles and improved target specificity. These modifications have led to the identification of several promising candidates for further clinical development.

The pharmacological profile of Isoquinoline, 1-methyl-, 2-oxide is further supported by computational studies that predict its binding interactions with biological targets. Molecular docking simulations have provided insights into how this compound interacts with proteins and enzymes relevant to various diseases. These computational approaches are increasingly being used to guide experimental designs and accelerate drug discovery processes.

The potential applications of Isoquinoline, 1-methyl-, 2-oxide extend beyond traditional pharmaceuticals into areas such as agrochemicals and material science. Its unique chemical properties make it a suitable candidate for developing novel pesticides and functional materials. Ongoing research is exploring these unconventional applications, which could open up new avenues for industrial utilization.

In conclusion, Isoquinoline, 1-methyl-, 2-oxide (CAS No. 3222-65-9) is a multifaceted compound with significant potential in medicinal chemistry and beyond. Its structural features and biological activities make it an attractive scaffold for drug development, while its synthetic accessibility allows for extensive modifications and derivative studies. As research continues to uncover new applications for this compound, it is likely to remain a cornerstone in the discovery of innovative therapeutic agents.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)